Sjukdomsbördan vid migrän

Mattias Linde MD, PhD, Professor

Norwegian Advisory Unit on Headaches, Institute of Neuroscience
Norwegian University of Science and Technology (NTNU), Trondheim

Tjörns Huvudvärksklinik

Svenska Neurologiveckan
Malmö 17 maj 2019
DN Debatt. ”Svenska huvudvärkspatienter nekas modern effektiv vård”
Migränanfallets dynamik

Linde M Migraine… Acta Neurol Scand 2006;114:71-83
Migraine demographics – sex and age

![Graph showing prevalence across age categories for women, men, and total population.]

Migraine severity varies

Severity groups (mean number attacks per year)

Percentage of attacks and of migraineurs

Attacks, n=6324
Migraineurs, n=423


GBD 2015 Neurological Disorders Collaborator Group

Findings Neurological disorders ranked as the leading cause group of DALYs in 2015 (250.7 [95% uncertainty interval (UI) 229.1 to 274.7] million, comprising 10.2% of global DALYs) and the second-leading cause group of deaths (9.4 [9.1 to 9.7] million, comprising 16.8% of global deaths). The most prevalent neurological disorders were tension-type headache (1505.9 [UI 1337.3 to 1681.6 million cases]), migraine (958.8 [872.1 to 1055.6] million), medication overuse headache (58.5 [50.8 to 67.4 million]), and Alzheimer’s disease and other dementias (46.0

Lancet Neurol 2017; 16: 877–97
Published Online September 17, 2017
http://dx.doi.org/10.1016/S1474-4422(17)30299-5
See Comment page 858
Figure 1: Global DALYs by age and neurological disorder in 2015
DALYs = disability-adjusted life-years.
## Figure 4: Ranking of age-standardised DALY rates for all neurological disorders by GBD region in 2015

Data are for both sexes. DALYs = disability-adjusted life-years.
World Health Organization  
Department of Information, Evidence and Research  
December 2016

Estimated DALYs (’000) by cause, sex and WHO Member State (1), 2015

<table>
<thead>
<tr>
<th>Sex</th>
<th>GHE code</th>
<th>GHE cause</th>
<th>Suriname</th>
<th>Swaziland</th>
<th>Sweden</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>B</td>
<td>C</td>
<td>D</td>
<td>E</td>
<td>F</td>
<td>G</td>
</tr>
<tr>
<td>1</td>
<td>Persons</td>
<td>920</td>
<td>10.</td>
<td>3.7</td>
<td>1.0</td>
<td>9.0</td>
</tr>
<tr>
<td>2</td>
<td>Persons</td>
<td>930</td>
<td>11.</td>
<td>0.7</td>
<td>1.3</td>
<td>14.5</td>
</tr>
<tr>
<td>3</td>
<td>Persons</td>
<td>940 F.</td>
<td>Neurological conditions</td>
<td>6.2</td>
<td>12.4</td>
<td>215.9</td>
</tr>
<tr>
<td>4</td>
<td>Persons</td>
<td>950 1.</td>
<td>Alzheimer disease and other dementias</td>
<td>1.9</td>
<td>1.1</td>
<td>129.5</td>
</tr>
<tr>
<td>5</td>
<td>Persons</td>
<td>960 2.</td>
<td>Parkinson disease</td>
<td>0.1</td>
<td>0.2</td>
<td>11.0</td>
</tr>
<tr>
<td>6</td>
<td>Persons</td>
<td>970 3.</td>
<td>Epilepsy</td>
<td>1.3</td>
<td>6.5</td>
<td>8.1</td>
</tr>
<tr>
<td>7</td>
<td>Persons</td>
<td>980 4.</td>
<td>Multiple sclerosis</td>
<td>0.0</td>
<td>0.1</td>
<td>6.2</td>
</tr>
<tr>
<td>8</td>
<td>Persons</td>
<td>990 5.</td>
<td>Migraine</td>
<td>2.1</td>
<td>3.5</td>
<td>34.8</td>
</tr>
<tr>
<td>9</td>
<td>Persons</td>
<td>1000 6.</td>
<td>Non-migraine headache</td>
<td>0.4</td>
<td>0.5</td>
<td>5.6</td>
</tr>
<tr>
<td>10</td>
<td>Persons</td>
<td>1010 7.</td>
<td>Other neurological conditions</td>
<td>0.4</td>
<td>0.6</td>
<td>20.8</td>
</tr>
<tr>
<td>11</td>
<td>Persons</td>
<td>1020 G.</td>
<td>Sense organ diseases</td>
<td>4.5</td>
<td>6.3</td>
<td>52.1</td>
</tr>
<tr>
<td>12</td>
<td>Persons</td>
<td>1030 1.</td>
<td>Glaucoma</td>
<td>0.2</td>
<td>0.2</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Konsekvenser i daglig tillvaro

Notera hur migrän drabbar centrala faktorer i livet hos dessa individer som valts slumpvis från hela Sverige.
QALY loss increases with migraine frequency


p=0.023
The cost of headache disorders in Europe: the Eurolight project

M. Linde\textsuperscript{a,b}, A. Gustavsson\textsuperscript{c}, L. J. Stovner\textsuperscript{a,b}, T. J. Steiner\textsuperscript{a,d}, J. Barré\textsuperscript{e}, Z. Katsarava\textsuperscript{f}, J. M. Lainez\textsuperscript{g}, C. Lamp\textsuperscript{h}, M. Lantéri-Minet\textsuperscript{i}, D. Rastenyte\textsuperscript{j}, E. Ruiz de la Torre\textsuperscript{k}, C. Tassorelli\textsuperscript{l} and C. Andrée\textsuperscript{d,m}

\textsuperscript{a}Department of Neuroscience, Norwegian University of Science and Technology, Trondheim; \textsuperscript{b}Norwegian National Headache Centre, St. Olavs University Hospital, Trondheim, Norway; \textsuperscript{c}i3Innovus, Stockholm, Sweden; \textsuperscript{d}Department of Neuroscience, Imperial College London, London, UK; \textsuperscript{e}Center of Public Health Research, CRP-Santé, Strassen, Luxembourg; \textsuperscript{f}Department of Neurology, University of Essen, Essen, Germany; \textsuperscript{g}Department of Neurology, Hospital Clínic Universitario, University of Valencia, Valencia, Spain; \textsuperscript{h}Department of Neurology and Pain Medicine, Konventhospital Barmherzige Brüder, Linz, Austria; \textsuperscript{i}Département d’Évaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, Nice, France; \textsuperscript{j}Lithuanian University of Health Sciences, Kaunas, Lithuania; \textsuperscript{k}Asociacion Española de Pacientes con Cefalea, Valencia, Spain; \textsuperscript{l}Centro Italiano di Ricerche Neurologiche Applicate (CIRNA) and Headache Science Centre, National Neurological Research Institute C. Mondino Foundation and University of Pavia, Pavia, Italy; and \textsuperscript{m}Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
Mean cost of migraine per sufferer

- Per-person cost: €1 222 / sufferer / year
- 93% indirect costs
- Top contributory category among direct costs: outpatient care (€30)

Societal cost increases with migraine frequency

Total costs (EU27) €112 billion each year

1. Migraine €50 billion
2. MOH €37 billion
3. TTH €21 billion
4. Other €3 billion

Context

# Headache service organisation

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Headache specialist centres</td>
<td>Advanced, multidisciplinary care Hospital-based</td>
</tr>
<tr>
<td>2. Special-interest headache care</td>
<td>Physicians with headache interest Outpatient care</td>
</tr>
<tr>
<td>1. General primary care</td>
<td>Primary health care providers Outpatient care</td>
</tr>
</tbody>
</table>

![Image](image.png)

Sjukdomsbördan vid migrän

Mattias Linde MD, PhD, Professor

Norwegian Advisory Unit on Headaches, Institute of Neuroscience
Norwegian University of Science and Technology (NTNU), Trondheim

Tjörns Huvudvärksklinik

Svenska Neurologiveckan
Malmö 17 maj 2019